Oncology APIs
Oncology APIs demand special care at every step, from synthesis to dispensing, because many are highly potent or cytotoxic. This sub-category lists a focused group of molecules covering several mechanisms. They include the kinase inhibitors Imatinib and Erlotinib, the proteasome inhibitor Bortezomib, the aromatase inhibitor Anastrozole, the immunomodulator Lenalidomide, and the cytotoxics Cyclophosphamide, Gemcitabine HCl and Irinotecan.
Buyers often need small quantities for development batches, so batch size and containment arrangements are part of the first conversation. Form also matters: imatinib is used as the mesylate, often in a defined crystal form, and injectable products need grades suited to sterile manufacture. Confirm the form, pharmacopoeia and impurity limits on your enquiry.
Oncology APIs are packed in sealed, labelled containers inside secondary packaging that limits exposure if damaged. Each lot ships with the manufacturer's COA and an SDS detailing handling precautions. We confirm any export or import permits before shipment.
Oncology APIs: questions buyers ask
What precautions apply when receiving cytotoxic APIs?
Why is the crystal form of imatinib mesylate specified?
Can I buy milligram quantities of an oncology API for research?
Nearby categories
Have a list of compounds to price?
Paste up to 200 CAS numbers into Bulk CAS lookup, or send one enquiry for everything in your quote list. We reply with price, lead time and documents.